AEVI GENOMIC MEDICINE, INC. (LON:MEDG) Files An 8-K Results of Operations and Financial Condition

Item 2.02.

On May 10, 2017, Aevi Genomic Medicine, Inc., a Delaware
corporation (the Company), issued a press release regarding its
financial results for the three months ended March 31, 2017. A
copy of this press release is attached hereto as Exhibit 99.1 and
is incorporated herein by reference.

As previously announced, the Company will host a conference call
and live audio webcast on Wednesday, May 10, at 8:30 a.m. EDT to
discuss first quarter 2017 financial results and to provide a
business update. The Company intends to refer to the slide
presentation, attached as Exhibit 99.2 and incorporated by
reference herein, on the conference call.

The slide presentation, together with an archive of the webcast,
will also be available for 30 days after the date of the
conference call in the Investor section of the Companys website
at www.aevigenomics.com.

This Current Report on Form 8-K, including the exhibits attached
hereto, contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, Section 21E of the
Securities Exchange Act of 1934 and as that term is defined in
the Private Securities Litigation Reform Act of 1995, which
include all statements other than statements of historical fact,
including (without limitation) those regarding the Companys
financial position, its development and business strategy, its
product candidates and the plans and objectives of management for
future operations. The Company intends that such forward-looking
statements be subject to the safe harbors created by such laws.
Forward-looking statements are sometimes identified by their use
of the terms and phrases such as estimate, project, intend,
forecast, anticipate, plan, planning, expect, believe, will, will
likely, should, could, would, may or the negative of such terms
and other comparable terminology. All such forward-looking
statements are based on current expectations and are subject to
risks and uncertainties. These risks and uncertainties include,
but are not limited to, those discussed in the section titled
Risk Factors of the Companys Annual Report on Form 10-K for the
year ended December 31, 2016. Should any of these risks or
uncertainties materialize, or should any of the Companys
assumptions prove incorrect, actual results may differ materially
from those included within these forward-looking statements.
Accordingly, no undue reliance should be placed on these
forward-looking statements, which speak only as of the date made.
The Company expressly disclaims any obligation or undertaking to
disseminate any updates or revisions to any forward-looking
statements contained herein to reflect any change in the Companys
expectations with regard thereto or any change in events,
conditions or circumstances on which any such statements are
based. As a result of these factors, the events described in the
forward-looking statements contained in this Current Report on
Form 8-K, including the exhibits attached hereto, may not occur.

(d) Exhibits. The following exhibits are furnished herewith:

to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.

Date: May 10, 2017

Exhibit Index

About AEVI GENOMIC MEDICINE, INC. (LON:MEDG)

Aevi Genomic Medicine, Inc., formerly Medgenics, Inc., is focused on genomic medicine. The Company is engaged in unlocking the potential of genomic medicine to translate genetic discoveries into therapies. The Company is engaged in developing therapies for children and adults with pediatric onset life altering diseases. The Company’s product candidates include AEVI-001 and AEVI-002. The Company’s research and development efforts leverage an internal genomics platform and a collaboration with the Center for Applied Genomics (CAG) at The Children’s Hospital of Philadelphia (CHOP). .

AEVI GENOMIC MEDICINE, INC. (LON:MEDG) Recent Trading Information

AEVI GENOMIC MEDICINE, INC. (LON:MEDG) closed its last trading session at 0.0000 with shares trading hands.